All data used for this research were extracted from the REIN registry, coordinated and supported by the French Biomedecine Agency. The access to national data is regulated by a scientific committee of French Biomedecine Agency which analyzes each request, and so cannot be made publicly available due to legal restrictions. Data are available upon request. If readers need information about the data from the REIN registry, they can contact Dr. Cecile Couchoud and Soraya SEKOURI who coordinate the REIN at the national level (email address: <cecile.couchoud@biomedecine.fr>, <soraya.sekouri@biomedecine.fr>).

Introduction {#sec005}
============

International guidelines don't recommend the use of a calcium concentration above 1.5 mmol/L that provides a per-dialysis calcium load and is associated with the progression of vascular calcification \[[@pone.0235135.ref001]\]. This worsening was correlated with the calcium load \[[@pone.0235135.ref002]\]. Similarly, the oral calcium supplementation is related to vascular calcifications progression and the switch to non-calcium phosphate-binders is followed by an improvement in their progression \[[@pone.0235135.ref003], [@pone.0235135.ref004], [@pone.0235135.ref005]\]. The 2003 Dialysis Outcomes Quality Initiative advised a 1.25 mmol/L dialysate calcium concentration and an oral calcium load of below 2 g including food intake \[[@pone.0235135.ref006]\]. The European Renal Association--European Dialysis and Transplant Association (ERA-EDTA) guidelines recommend a personalized dialysate calcium concentration \[[@pone.0235135.ref007]\]. Lastly, the Kidney Disease Improving Global Outcomes (KDIGO) 2009 guidelines advised a dialysate calcium concentration varying from 1.25 to 1.5 mmol/L but the recommendation was graded 2D \[[@pone.0235135.ref008]\]. The KDIGO 2017 guidelines give little advice on this topic, and simply state that 1.25 mmol/L is the calcium concentration that allows a neutral calcium balance \[[@pone.0235135.ref009]\].

In the Dialysis Outcome Practice Patterns Study (DOPPS) published in 2008, a 1.25 mmol/L dialysate calcium concentration was used in less than 5% of centers in France, and the 1.75 mmol/L was still frequently used \[[@pone.0235135.ref010]\]. We conducted a nationwide observational, longitudinal study on the use of dialysate calcium concentrations and of the mineral bone disease (MBD) treatment over the 2010--2014 period in France and their relations with survival.

Methods {#sec006}
=======

Population {#sec007}
----------

Data are extracted from REIN registry, which includes all patients with end-stage kidney disease in France on chronic renal replacement therapy. Details of methods and quality control of the REIN registry have been described elsewhere \[[@pone.0235135.ref011]\]. Data were fully anonymized. Approvals from the National Commission on Informatics and Liberty and from the Advisory Committee on Information Processing in Material Research in the Field of Health were obtained through the national REIN registry. The patients have an opt out option if they don\'t want to be included into the registry and the patients associations are participating to the monitoring of the registry. We included all incident adult patients having initiated dialysis between January 1^st^, 2010, and December 31^st^, 2013, and who were dialyzed for more than 3 months (flow chart, [Fig 1](#pone.0235135.g001){ref-type="fig"}).

![Flow chart.](pone.0235135.g001){#pone.0235135.g001}

Calcium dialysate exposure {#sec008}
--------------------------

Exposures to the different dialysate calcium concentrations were constructed from the sales data. All the dialysate manufacturers operating in France (Soludia Bellco now Medtronic, Fresenius, Baxter-Gambro, Hemotech, Fresenius Medical Care, and BBraun) provided the number, the calcium concentration and the acid type of dialysate bags sold by year and by dialysis center from 2010 to 2014. The calcium load from citric acid dialysate is lower than the one from standard acetic acid dialysate or HCl dialysate; to deliver the same calcium load, the calcium concentration of a citric acid dialysate has to be about 0.15 mmol/l higher than in the other two dialysates. Because the purpose of the study is to analyze the effect of the calcium load on survival, the citric dialysate was systematically reclassified to a -0.15 mmol/L lower calcium concentration. The dialysis centers were classified yearly with regard to their percentage use of standard, citric acid and hydrochloric acid dialysates (100% standard dialysate being the reference).

To ensure the quality of the exposure assessment, we compared the number of patients on hemodialysis estimated from the yearly dialysate volume sold to each unit with the number of patients actually reported each year by the units to the REIN registry. For each dialysis unit, we calculated the ratio of the number of dialysis patients provided by the national registry to the number estimated from the volume of dialysate sold; this ratio defined the percentage of dialysate exposure by center and by year. Dialysate exposure ratios \< 1.2 were considered accurate, reflecting that reported sales covered dialysis needs. Patients who started dialysis in a unit with a ratio \>1.2 were not included in the study or were censored at the time that dialysate exposure data were considered inaccurate.

Exposure at the unit level was assigned at the patient level by time period according to the yearly changes of dialysate exposure by center and to each patient\'s changes of dialysis center.

MBD therapies {#sec009}
-------------

Individual data on MBD therapies were extracted from French national health database which retrieved the therapies bought by each subject in number of canister per month, recalculated as a dose per day. This access allows evaluating therapies exposure by day and by drugs dose. Oral calcium, native and active vitamin D (1α calcidol), sevelamer, lanthanum and cinacalcet were studied. On the 25629 subjects included, 21497 patients were identified in the database. In the lack of unique identifier between French national health database and the REIN registry database, we proceeded to a stepwise indirect linkage using the following data: gender, age, residency code, a national hospital identifier, and date of dialysis start.

Data {#sec010}
----

The REIN data at dialysis start included age, gender, nephropathy, emergency start, laboratory results (albumin, hemoglobin, and estimated glomerular filtration rate (eGRF)), and comorbidities. We used the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation to calculate eGFR. Baseline comorbidities included active malignancy, cirrhosis, handicap status, obesity (body mass index ≥30 kg/m^2^), arrhythmia, respiratory insufficiency, heart failure, and at least one arterial disease (among stroke, transient ischemic attack, coronary insufficiency, abdominal aortic aneurysm, and lower limb arteritis). Furthermore, treatment data including frequency and duration of dialysis, hemodiafiltration use, vascular access and center type (center, medicalized unit or self-assisted unit) were updated annually and when the patient moved to another dialysis center. The events registered included kidney transplantation, transfer to peritoneal dialysis, weaning from dialysis, and death through December 31, 2014.

Statistical analysis {#sec011}
--------------------

Patient's baseline characteristics and technical data were compared according to dialysate calcium exposure at dialysis start in 2 groups: mainly exposed to a calcium concentration ≤1.5 mmol/L or \>1.5 mmol/l. MBD therapies are shown at baseline in these 2 groups and on the subgroups of 8179 subjects followed for at least 3 years. Categorical and continuous covariates at inclusion were compared between groups using Fisher exact test, Pearson Chi-Square or one-way ANOVA as appropriate. Crude events rates were described according to dialysate calcium exposure at baseline in 2 groups ≤1.5 mmol/L or \>1.5 mmol/L (gathering 1.6 and 1.75 mmol/L).

We used Cox proportional hazard risk models to estimate hazard ratios (HR) and their 95% confidence intervals (95% CI) for all-cause mortality associated with the time-varying dialysate calcium and MBD therapies exposures. The percentage of use per center of dialysate calcium lower and higher than 1.5 mmol/L, and the MBD therapies were analyzed in tertiles, zero use being the reference. The Cox models were stratified by center type. The Cox model was also adjusted for age, gender, co-morbidities, dialysis start in emergency, biological covariates at dialysis start, vascular access type, dialysis session length, hemodiafiltration, number of dialysis sessions per week. These last four variables were also included as time-dependent covariates. Because some unknown patient characteristics and medical practice patterns may vary by unit, robust variance estimates (by a sandwich estimator) were used to account for unit clustering effect \[[@pone.0235135.ref012]\]. The proportionality hazards assumption was tested by the Schoenfeld residual method. Survival times were censored at the time of event for kidney transplantation, weaning from dialysis, loss to follow-up, moving out of France, transfer to a dialysis unit with inaccurate dialysate exposure, peritoneal dialysis, or home dialysis.

The all-cause and cardiovascular mortality models were lastly adjusted for the dialysate acid type classified yearly for citric acid, HCl and standard as a time dependent covariate.

Missing values on adjustment covariates were treated by multiple imputations using multivariate imputation by chained equations (MICE, packages mice and miceadds of R). Twenty iterations were used and 20 imputed datasets were created. All covariates presented in the Cox models were included in the imputation procedure. Sixty percent of patients had at least one missing data on adjustment covariates. Each Cox model was performed on the 20 imputed datasets and these results were pooled by Rubin's rules.

All tests were two-tailed, and the threshold for statistical significant was set to p\<0.05. All statistical analyses were performed with SAS software (version 9.4) and R software.

Results {#sec012}
=======

The exposure was dominated by the 1.5 mmol/L concentration with 3.3 millions of dialysate bags sold in 2010 and up to 4.5 millions in 2014 ([Fig 2](#pone.0235135.g002){ref-type="fig"}). The \>1.5 mmol/L concentration decreased from 1.9 million bags to 1.5 million whereas \<1.5 mmol/L increased from 0.2 to 0.7 million bags during the same period. In 2010, the \<1.50 mmol/L concentration was used at a median level of 2.5% in each center (IQR 0.6%-4.2%) that slightly increased after to 4.4% (IQR 2%-11.7%). The \>1.5 mmol/L was used at a median level of 24.5% by center (IQR 11%-45.2%) that decreased thereafter to 15.1% (IQR 6.7%-34.3%, [Fig 3](#pone.0235135.g003){ref-type="fig"}).

![Overall sales of dialysate in France from 2010 to 2014, as a function of the calcium concentration.](pone.0235135.g002){#pone.0235135.g002}

![Boxplots of the dialysis units' percentage use of dialysate calcium concentrations between 2010 and 2014.](pone.0235135.g003){#pone.0235135.g003}

The 1.5 mmol/L was used in 97 to 99% of the dialysis centers on the study period and was the main dialysate in 81 to 83% of the centers ([Table 1](#pone.0235135.t001){ref-type="table"}). However and applying European guidelines for a personalized prescription, 78 to 86% of the dialysis centers from 2010 to 2014 used concomitantly 3 calcium concentrations, \<1.5, 1.5 and \>1.5 mmol/L which was the most frequent combination. The second most frequent combination was 1.5 and \>1.5 mmol/L, used in 5 to 12% of the centers. The use of a unique calcium concentration remained rare as the combination of 2 concentrations that included \<1.5 mmol/L. Still 19% in 2010 to 14% in 2014 of the dialysis centers used \>1.5 mmol/L as the main dialysate, percentage that decreased on the time period to the profit of the combination of 3 dialysates that steadily increased. Citric dialysate after requalification of the calcium concentration was the most frequently dialysate used with a concentration \<1.5 mmol/L and standard dialysate was the most used with a concentration \>1.50 mmol/L ([Table 2](#pone.0235135.t002){ref-type="table"}).

10.1371/journal.pone.0235135.t001

###### Dialysate calcium concentrations by dialysis center in France from 2010 to 2014.
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  N = 1214                              2010 (N = 1080)   2011 (N = 1091)   2012 (N = 1120)   2013 (N = 1119)   2014 (N = 1118)
  ------------------------------------- ----------------- ----------------- ----------------- ----------------- -----------------
  **Uses (several answers possible)**                                                                           
      Ca\<1.5 mmol/L                    82% (886)         84% (912)         84% (942)         89% (997)         91% (1016)
      Ca = 1.5                          97% (1045)        97% (1062)        98% (1103)        99% (1113)        98% (1101)
      Ca\>1.5                           94% (1015)        93% (1017)        92% (1028)        93% (1042)        92% (1028)
  **Combinations used**                                                                                         
      Ca\<1.5 mmol/L                    \-                \-                \-                0.1% (1)          0.3% (3)
      Ca = 1.5                          4% (41)           5% (54)           5% (59)           4% (50)           3% (38)
      Ca\>1.5                           2% (18)           0.9% (10)         1% (15)           \-                0.4% (4)
      Ca\<1.5/Ca = 1.5                  2% (24)           2% (20)           3% (33)           2% (26)           4% (49)
      Ca = 1.5/Ca\>1.5                  12% (135)         11% (115)         9% (104)          6% (72)           5% (60)
      Ca\<1.5/Ca\>1.5                   2% (17)           2% (19)           0.2% (2)          0.4% (5)          0.9% (10)
      Ca\<1.5/Ca = 1.5/Ca\>1.5          78% (845)         80% (873)         81% (907)         86% (965)         85% (954)
  **Majority use**                                                                                              
      Ca \< 1.5 mmol/L                  \-                \-                0.1% (1)          0.4% (5)          4% (42)
      Ca = 1.5                          81% (870)         82% (894)         83% (926)         82% (922)         82% (916)
      Ca \>1.5                          19% (210)         18% (197)         17% (193)         17% (192)         14% (160)

Data are quoted as the percentage of the dialysis units (N = 1214 at baseline, although centers with poorly defined dialysate exposure were excluded as the study went on).

10.1371/journal.pone.0235135.t002

###### Percentage of dialysate sales in France from 2010 to 2014, as a function of the calcium concentration and acid type.
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         Acetate   HCl   Citrate                                 
  ------ --------- ----- --------- ---- ----- ----- ------ ----- -----
  2010   4%        61%   35%       3%   76%   21%   \-     \-    \-
  2011   3%        67%   30%       2%   78%   19%   100%   \-    \-
  2012   4%        70%   27%       3%   86%   12%   99%    \-    1%
  2013   4%        72%   25%       2%   90%   8%    76%    14%   10%
  2014   3%        73%   23%       2%   84%   14%   73%    8%    19%

Baseline patients characteristics differed between the 2 groups ≤1.5 mmol/L or \>1.5 mmol/L of dialysate calcium for diabetes, arterial disease, initial nephropathy, start in emergency, hemodiafiltration use, vascular access, units types, sessions per week, sessions time, CKD-EPI eGFR and dialysate acid type ([Table 3](#pone.0235135.t003){ref-type="table"}). Native vitamin D was the most frequent MBD therapy prescribed to 56% of the subjects during the first year ([Table 4](#pone.0235135.t004){ref-type="table"}), being less prescribed in the \>1.5 mmol/L dialysate group. Active vitamin D was far less prescribed in 15.8% at a median dose of 0.23 μg/d (IQR 0.1--0.35). Oral calcium was prescribed to 42% of the subjects at a median dose of 997 mg/d (IQR 508--1736) during the first year and at a higher dose and more frequently in the \>1.50 mmol/L dialysate group. This latter group was therefore exposed to a markedly higher calcium load. Sevelamer was the most frequent non-calcium based phosphate binder used, prescribed to 30.7% of the patients during the first year at a median dose of 2526 mg/d (IQR 1419--3975). Finally, lanthanum was used by 10.9% of the subjects at a median dose of 1098 mg/d (IQR 506--1849) during the first year. The phosphate binders were slightly more prescribed in the ≤1.5 mmol/L dialysate calcium group. Cinacalcet was the less frequently MBD therapy prescribed to 8.4% of the subjects, slightly more in the ≤1.5 mmol/L dialysate calcium group and surprisingly at a median dose of 27 mg/d (IQR 14--37) lower than the first pill dosage.

10.1371/journal.pone.0235135.t003

###### Characteristics of the population at dialysis initiation, as extracted from the REIN registry after multiple imputations and as a function of the main dialysate calcium concentration used in the baseline unit.

![](pone.0235135.t003){#pone.0235135.t003g}

                                                                 Main facility-level dialysate Ca concentration mmol/L                                 
  ------------------------------------------ ------------------- ------------------------------------------------------- ------------------- --------- -------
  Age (years)                                70.4 (59.1--79.4)   70.3 (59--79.5)                                         70.8 (59.7--79.2)   0.376     
  Sex (% males)                              63% (16140)         63% (12950)                                             62% (3190)          0.429     
  Diabetes                                   42% (10786)         42% (8525)                                              44% (2261)          \<0.001   129
  Respiratory failure                        14% (3662)          14% (2922)                                              14% (739)           0.685     824
  Cirrhosis                                  2% (534)            2% (445)                                                2% (89)             0.069     694
  Cancer                                     11% (2889)          11% (2324)                                              11% (565)           0.618     687
  Heart failure                              25% (6319)          25% (5085)                                              24% (1234)          0.396     658
  Cardiac rhythm disorder                    21% (5414)          21% (4330)                                              21% (1083)          0.858     708
  Peripheral arterial disease                39% (9962)          39% (7905)                                              40% (2057)          0.021     
  Body mass index ≥ 30 kg/m^2^               23% (5797)          23% (4622)                                              23% (1175)          0.498     5730
  Walking                                                                                                                                    0.88      2545
      Normal                                 82% (21096)         82% (16904)                                             82% (4192)                    
      Able with help                         13% (3314)          13% (2650)                                              13% (664)                     
      Unable with help                       5% (1219)           5% (971)                                                5% (249)                      
  Nephropathy                                                                                                                                \<0.001   
      Vascular or hypertensive nephropathy   27% (6896)          27% (5610)                                              25% (1286)                    
      Diabetic nephropathy                   23% (5966)          23% (4693)                                              25% (1273)                    
      Glomerulopathies                       10% (2633)          11% (2165)                                              9% (468)                      
      Polycystic kidney disease              6% (1526)           6% (1231)                                               6% (295)                      
      Tubulointerstitial nephropathy         4% (1082)           4% (871)                                                4% (211)                      
      Other or unknown diseases              29% (7526)          29% (5954)                                              31% (1572)                    
  Emergency dialysis initiation              32% (8119)          31% (6431)                                              33% (1688)          0.022     1377
  Hemodiafiltration                          12% (2986)          12% (2512)                                              9% (474)            \<0.001   
  Vascular access                                                                                                                            \<0.001   1436
      Native fistula or graft                53% (13466)         52% (10732)                                             54% (2734)                    
      Catheter                               41% (10527)         42% (8571)                                              38% (1956)                    
      Other                                  6% (1635)           6% (1221)                                               8% (415)                      
  Unit type                                                                                                                                  0.006     
  Centre                                     91% (23335)         91% (18746)                                             90% (4589)                    
      Medicalized unit                       3% (800)            3% (607)                                                4% (193)                      
      Self dialysis unit                     2% (420)            2% (329)                                                2% (91)                       
      Training                               4% (1074)           4% (842)                                                5% (232)                      
  Sessions per week                                                                                                                          \<0.001   176
      2                                      6% (1608)           7% (1379)                                               4% (229)                      
      3                                      92% (23685)         92% (18865)                                             94% (4820)                    
      Other                                  1% (336)            1% (280)                                                1% (55)                       
  Dialysis time \> 4 hours                   3% (717)            2% (471)                                                5% (246)            \<0.001   161
  Albuminemia (g/l)                                                                                                                          0.601     10152
      \<25                                   11% (2781)          11% (2217)                                              11% (563)                     
       \[25;30\[                             18% (4675)          18% (3738)                                              18% (937)                     
       \[30;35\[                             30% (7638)          30% (6160)                                              29% (1479)                    
      \> = 35                                41% (10535)         41% (8409)                                              42% (2125)                    
  Hemoglobin level (g/dl)                    10.1 (9--11.1)      10.1 (9--11.1)                                          10 (9--11.1)        0.387     4837
  eGFR\> 10 ml/min/1.75m2                    26% (6766)          27% (5458)                                              26% (1308)          0.184     3863

Data are presented as the median \[interquartile range (IQR)\] or the percentage (n). The p-value was calculated with Fisher's exact test, Pearson's chi-squared test or a one-way analysis of variance, as appropriate. Peripheral arterial disease included stroke, transient ischemic attack, coronary heart failure, aneurysm of the abdominal aorta or arteritis of the lower limbs. CKD-EPI eGFR: the glomerular filtration rate estimated using the Chronic Kidney Disease-Epidemiology Collaboration equation.

10.1371/journal.pone.0235135.t004

###### First-year medication prescriptions as a function of the primary facility-level dialysate calcium concentration at baseline, for the 21497 patients identified in the French national health database.
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                                               Main facility-level dialysate Ca concentration   
  ------------------------ ------------------- ------------------------------------------------ -------------------
  **Active vitamin D**                                                                          
  \% of patients exposed   15.8%               15.7%                                            16%
  Dose μg/d                0.23 (0.1--0.35)    0.24 (0.1--0.37)                                 0.21 (0.08--0.29)
  **Native vitamin D**                                                                          
  \% of patients exposed   56%                 57%                                              51.8%
  Dose UI/d                1948 (986--3288)    1953 (989--3288)                                 1920 (910--3231)
  **Calcium**                                                                                   
  \% of patients exposed   42.8%               41.9%                                            46.4%
  Dose mg/d                997 (508--1736)     986 (506--1721)                                  1035 (530--1779)
  **Cinacalcet**                                                                                
  \% of patients exposed   8.4%                8.5%                                             7.9%
  Dose mg/d                27 (14--37)         27 (15--38)                                      25 (11--35)
  **Lanthanum**                                                                                 
  \% of patients exposed   10.9%               11%                                              10.4%
  Dose mg/d                1098 (506--1849)    1085 (500--1878)                                 1125 (536--1737)
  **Sevelamer**                                                                                 
  \% of patients exposed   30.7%               30.8%                                            29.9%
  Dose mg/d                2526 (1419--3975)   2526 (1412--4012)                                2549 (1426--3945)

data are presented as (i) the percentage of patients having received the drug, and (ii) the median \[interquartile range\] daily dose among patients having received the drug.

In the subgroup of patients with at least 3 years of follow-up data, the prescription frequency and median dose fell over time for native vitamin D, oral calcium, phosphate binders and active vitamin D ([Table 5](#pone.0235135.t005){ref-type="table"}). For example, the prescription frequency and median \[IQR\] dose of oral calcium fell from 47% to 34% and from 1068 mg/day \[577--1801\] to 829 mg/day \[411--1493\], respectively. The prescription frequency and median \[IQR\] dose of sevelamer fell from 33.5% to 26.9% and from 2762 mg/day \[1578--4267\] to 2323 mg/day \[1184--3748\], respectively. These courses combined the prescription and the adherence trends. Cinacalcet was the only MBD treatment prescribed more frequently during the follow-up period, although the median dose remained abnormally low.

10.1371/journal.pone.0235135.t005

###### Medications prescriptions as a function of the main facility-level dialysate calcium concentration, for the 8179 patients with at least 3 years of follow-up and having been identified in the French national health database.
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                                Year of follow-up                                                     
  ----------------------------- ---------------------------------- ---------------------------------- ----------------------------------
  **Active vitamin D (μg/d)**   \% Median **μg/d** (IQR)           \% Median **μg/d** (IQR)           \% Median **μg/d** (IQR)
      Total                     19.4% 0.24 (0.1--0.37)             14% 0.25 (0.12--0.37)              11.7% 0.23 (0.12--0.35)
      Ca ≤ 1.5 mmol/L           19.2% 0.25 (0.11--0.39)            14% 0.25 (0.12--0.37)              11.8% 0.23 (0.12--0.35)
      Ca \> 1.5 mmol/L          20.1% 0.22 (0.08--0.3)             14.1% 0.21 (0.1--0.29)             11.6% 0.23 (0.14--0.35)
  **Native vitamin D (UI/d)**   \% Median (IQR)                    \% Median (IQR)                    \% Median (IQR)
      Total                     59% 2067 **UI/d** (1096--3288)     57.1% 1918 **UI/d** (822--3014)    50.4% 1644 **UI/d** (822--2904)
      Ca ≤ 1.5 mmol/L           60.3% 2077 **UI/d** (1111--3289)   58.1% 1918 **UI/d** (826--3014)    51.4% 1644 **UI/d** (822--2879)
      Ca \> 1.5 mmol/L          54.5% 2046 **UI/d** (907--3288)    53% 1808 **UI/d** (822--2999)      46.2% 1668 **UI/d** (822--3014)
  **Calcium (mg/d)**            \% Median (IQR)                    \% Median (IQR)                    \% Median (IQR)
      Total                     47.4% 1068 **mg/d** (577--1801)    40.4% 928 **mg/d** (493--1578)     34.3% 829 **mg/d** (411--1493)
      Ca ≤ 1.5 mmol/L           45.9% 1068 **mg/d** (575--1777)    39.9% 928 **mg/d** (493--1578)     33.8% 835 **mg/d** (411--1493)
      Ca \> 1.5 mmol/L          52.3% 1046 **mg/d** (594--1825)    42.9% 904 **mg/d** (493--1529)     36.5% 822 **mg/d** (411--1519)
  **Cinacalcet (mg/d)**         \% Median (IQR)                    \% Median (IQR)                    \% Median (IQR)
      Total                     9.4% 28 **mg/d** (15--37)          12.8% 25 **mg/d** (14--38)         13.2% 25 **mg/d** (14--35)
      Ca ≤ 1.5 mmol/L           9.6% 28 **mg/d** (16--40)          12.8% 28 **mg/d** (14--39)         13.3% 25 **mg/d** (14--34)
      Ca \> 1.5 mmol/L          8.8% 25 **mg/d** (14--34)          12.7% 23 **mg/d** (12--35)         12.9% 26 **mg/d** (12--39)
  **Lanthanum (mg/d)**          \% Median (IQR)                    \% Median (IQR)                    \% Median (IQR)
      Total                     12.4% 1171 **mg/d** (554--1849)    12.1% 992 **mg/d** (493--1807)     10.3% 952 **mg/d** (493--1726)
      Ca ≤ 1.5 mmol/L           12.6% 1154 **mg/d** (534--1911)    12.2% 998 **mg/d** (493--1826)     10.5% 925 **mg/d** (493--1726)
      Ca \> 1.5 mmol/L          11.9% 1220 **mg/d** (608--1788)    11.4% 986 **mg/d** (493--1792)     9.2% 1163 **mg/d** (691--1726)
  **Sevelamer (mg/d)**          \% Median (IQR)                    \% Median (IQR)                    \% Median (IQR)
      Total                     33.5% 2762 **mg/d** (1578--4267)   31.4% 2367 **mg/d** (1184--3945)   26.9% 2323 **mg/d** (1184--3748)
      Ca ≤ 1.5 mmol/L           34% 2762 **mg/d** (1582--4299)     31.2% 2367 **mg/d** (1184--3945)   26.6% 2348 **mg/d** (1184--3854)
      Ca \> 1.5 mmol/L          31.8% 2618 **mg/d** (1554--4142)   32.1% 2361 **mg/d** (1184--3551)   28.3% 2170 **mg/d** (1184--3551)

data are presented as (i) the percentage of patients having received the drug, and (ii) the median \[interquartile range\] daily dose among patients having received the drug.

The death and transplantation rates for 100 person-years were quite similar between the groups ≤1.5 mmol/L and the \>1.5 mmol/L as the other events ([Table 6](#pone.0235135.t006){ref-type="table"}). In the full adjusted Cox analyses, the dialysate calcium concentrations did not influence survival ([Table 7](#pone.0235135.t007){ref-type="table"}). Using 2 or 3 calcium formulas compared to one brought no survival benefit (HR 1.14 95%CI 0.85--1.52 for 2 formulas, HR 1.04 95%CI 0.78--1.4 for 3 formulas).

10.1371/journal.pone.0235135.t006

###### Person-years of exposure and percentages of events, by dialysate group at baseline.

![](pone.0235135.t006){#pone.0235135.t006g}

                                               Main facility-level calcium concentration at baseline   
  -------------------------------------------- ------------------------------------------------------- ------------
  Person-years of exposure                     36667.4                                                 9764.1
  **Events% (n)**                                                                                      
      At home                                  0.2% (51)                                               0.2% (8)
      Deceased                                 27% (5495)                                              28% (1451)
      Loss to follow-up                        0.4% (84)                                               0.4% (19)
      Moved out to France                      0% (6)                                                  0.1% (7)
      Switched to peritoneal dialysis          0.9% (188)                                              0.7% (35)
      Switched to a censored dialysis center   5% (1045)                                               4% (227)
      Transplanted                             12% (2475)                                              12% (598)
      Discontinuation of dialysis              4% (767)                                                4% (208)
      Total events                             49% (10111)                                             50% (2553)
  **Rate for 100 person-years**                                                                        
      Mortality rate                           15%                                                     14.9%
      Transplantation rate                     6.7%                                                    6.1%

10.1371/journal.pone.0235135.t007

###### Fully adjusted hazard ratio (HR) for all-cause and cardiovascular mortality, as a function of exposure to dialysate and to MBD treatments.

![](pone.0235135.t007){#pone.0235135.t007g}

                                                                                       Person-years   All-cause mortality
  ------------------------------------------------------------------------------------ -------------- ---------------------------------------------------------
  \% of dialysate with Ca\<1.5 mmol/L[^1^](#t007fn002){ref-type="table-fn"} (ref: 0)   7654           
      \]0%;2%\]                                                                        12168          1\[0.9;1.12\]
      \]2%;6%\]                                                                        15094          1.01 \[0.9--1.14\]
      \>6%                                                                             11516          1.05 \[0.94;1.18\]
  \% of dialysate with Ca\>1.5 mmol/L[^1^](#t007fn002){ref-type="table-fn"} (ref: 0)   4337           
      \]0;10%\]                                                                        13571          0.95 \[0.84;1.07\]
      \]10%;30%\]                                                                      13805          0.96 \[0.85;1.1\]
      \>30%                                                                            14718          0.93 \[0.82;1.06\]
  Calcium (mg/d, ref: 0)[^1^](#t007fn002){ref-type="table-fn"}                         32110          
      \]0; 600\[                                                                       4750           1.21 \[1.11;1.32\][\*](#t007fn003){ref-type="table-fn"}
       \[600; 1200\[                                                                   4080           0.77 \[0.69;0.86\][\*](#t007fn003){ref-type="table-fn"}
      ≥ 1200                                                                           5491           0.35 \[0.31;0.4\][\*](#t007fn003){ref-type="table-fn"}
  Active vitamin D (μg/d, ref: 0)[^1^](#t007fn002){ref-type="table-fn"}                41472          
      \]0; 0,15\[                                                                      1736           1.35 \[1.2;1.51\][\*](#t007fn003){ref-type="table-fn"}
       \[0,15; 0,3\[                                                                   1827           0.77 \[0.64;0.92\][\*](#t007fn003){ref-type="table-fn"}
      ≥ 0,3                                                                            1397           0.62 \[0.46;0.83\][\*](#t007fn003){ref-type="table-fn"}
  Native vitamin D (UI/d, ref: 0)[^1^](#t007fn002){ref-type="table-fn"}                27229          
      \]0; 1200\[                                                                      6661           1.15 \[1.07;1.25\][\*](#t007fn003){ref-type="table-fn"}
       \[1200; 2400\[                                                                  5256           0.65 \[0.59;0.71\][\*](#t007fn003){ref-type="table-fn"}
      ≥ 2400                                                                           7285           0.24 \[0.21;0.28\][\*](#t007fn003){ref-type="table-fn"}
  Sevelamer (mg/d, ref: 0)[^1^](#t007fn002){ref-type="table-fn"}                       36318          
      \]0; 1600\[                                                                      3463           1.34 \[1.24;1.46\][\*](#t007fn003){ref-type="table-fn"}
       \[1600; 3200\[                                                                  3344           0.62 \[0.54;0.7\][\*](#t007fn003){ref-type="table-fn"}
      ≥ 3200                                                                           3307           0.28 \[0.23;0.35\][\*](#t007fn003){ref-type="table-fn"}
  Lanthanum (mg/d, ref: 0)[^1^](#t007fn002){ref-type="table-fn"}                       42957          
      \]0; 600\[                                                                       1126           1.10 \[0.95;1.26\]
       \[600; 1200\[                                                                   905            0.86 \[0.71;1.04\]
      ≥ 1200                                                                           1444           0.31 \[0.24;0.41\][\*](#t007fn003){ref-type="table-fn"}
  Cinacalcet (mg/d, ref: 0)[^1^](#t007fn002){ref-type="table-fn"}                      43082          
      \]0; 20\[                                                                        1302           1.22 \[1.05;1.42\][\*](#t007fn003){ref-type="table-fn"}
       \[20; 30\[                                                                      939            0.5 \[0.37;0.68\][\*](#t007fn003){ref-type="table-fn"}
      ≥ 30                                                                             1108           0.39 \[0.28;0.54\][\*](#t007fn003){ref-type="table-fn"}
  Missing medication                                                                   7591           0.75 \[0.7;0.81\][\*](#t007fn003){ref-type="table-fn"}

Stratified by the center modalities of treatment^1^. Adjusted for hemodiafiltration^1^, number of sessions per week^1^, vascular access^1^, dialysis time \> 4 hours^1^, sex, respiratory failure, cardiac failure, cirrhosis, cancer, cardiac rhythm disorder, peripheral arterial disease (stroke, transient ischemic attack, coronary failure, aneurysm abdominal aorta or arteritis of the lower limbs), obesity, mobility, initial nephropathy, emergency dialysis initiation, eGFR\>10 ml/min/1.75m^2^, hemoglobin level, albuminemia class.

^1^: time-dependent covariates

\*: p\<0.05

A daily dose in the second and third tertiles of calcium, active vitamin D, native vitamin D, sevelamer, lanthanum, cinacalcet were associated with decreased HRs for all-cause mortality ([Table 7](#pone.0235135.t007){ref-type="table"}). Accordingly the cardiovascular mortality HR was decreased by a daily dose of these drugs in the same tertiles. Surprisingly some of the first tertiles of these drugs were associated with a deleterious effect.

Discussion {#sec013}
==========

First of all, we depicted the landscape of the mineral bone disease therapies at the patient level and the use of the dialysate calcium concentrations at the center level in our country from 2010 to 2014. Dialysate \>1.5 mmol/L remained prescribed more than the dialysate \<1.5 mmol/L known to avoid a calcium load during the session. The \> 1.5 dialysate was however not associated with a worse survival in our study. Nephrologists were trained in programs employing several formulas of dialysate calcium, the combination of 3 ones being common. ERA-EDTA guidelines recommend a personalized prescription of the dialysate calcium. Our full adjusted Cox models did not evidence a relevant survival benefit associated with centers that used more than one dialysate calcium concentration. Lastly, most of the MBD treatments were associated with longer survival.

Our results for the dialysate calcium concentration contrast with recent observational and randomized studies. The DOPP Study evidenced a mortality risk increased by 13% with a high dialysate calcium and a lower risk of parathyroidectomy \[[@pone.0235135.ref013]\]. One cohort study found a cardiovascular mortality risk multiplied by 5.44 (95%CI 2.5--11.7) associated with the use of 1.75 mmol/l dialysate calcium in subjects having a high PTH level at inclusion \[[@pone.0235135.ref014]\]. One register study on 1182 subjects incident in dialysis associated the use of 1.75 mmol/L dialysate calcium with an all-cause mortality HR of 3.67 (95%CI 1.7--7.5) compared to the 1.25 mmol/L formula and of 2.23 (95%CI 1.2--3.9) compared to the 1.5 mmol/L, results confirmed in a subset of patients matched by a propensity score \[[@pone.0235135.ref015]\]. To the best of our knowledge, the association between survival and dialysate calcium has not been assessed in recent randomized studies. One trial evaluated the coronary artery calcifications of subjects randomized to 1.25 mmol/L versus 1.75 mmol/L and evidenced the higher progression rate when dialyzed with 1.75 mmol/L, especially in patients with uncontrolled phosphatemia \[[@pone.0235135.ref001]\]. Our study was unable to evidence any benefit from the use of 1.25 mmol/L formula probably because of its scarce use with a median percentage per unit below 5%. One randomized study having included patients with parathyroid hormone lower than 2 x normal showed a faster progression of the vascular calcifications in subjects dialyzed with 1.5 mmol/l instead of 1.25 \[[@pone.0235135.ref016]\]. Lastly, a North-American study analyzed dialysis centers using a very low dialysate calcium concentration (1.0 mmol/L) and defined a facility level covariate \[[@pone.0235135.ref017]\]. They found that those using 1.25 mmol/L in less than 75% of the subjects, the remaining being dialyzed on 1.0 mmol/L had a similar mortality risk than those using 1.25 mmol/L in more than 75% of the subjects. However, hospitalizations for cardiac failure, hypotension, hypocalcemia, and the use of MBD treatments were more frequent with the 1.00 mmol/l formula.

Similarly to the low dialysate calcium, the calcium free phosphate binders were shown to slow the vascular calcifications rate \[[@pone.0235135.ref005], [@pone.0235135.ref018], [@pone.0235135.ref019]\]. This effect might be a useful surrogate endpoint for survival. In a recent meta-analysis, sevelamer lowered mortality compared to calcium \[[@pone.0235135.ref020]\]. We have however no proof of the superiority of sevelamer over placebo because the initial trials did not feature a placebo arm. Therefore we cannot be totally confident that these trials evidenced the harmful effect of calcium or/and the benefit from sevelamer. In the present observational study, both treatments appeared to be beneficial on survival. Probably the calcium based phosphate-binder benefit should also be viewed in the perspective of a median dose around 1 g/d that remained very much lower than the dose prescribed in the past and that was evidenced to be deleterious \[[@pone.0235135.ref003], [@pone.0235135.ref004]\]. For most of the studied drugs, the first tertile was rather associated with a negative effect on survival that has to be interpreted cautiously. That might have been due to unnecessary prescriptions with more side effects than benefits or poor adherence. Conversely, the large benefit observed with the second and third tertiles for MBD treatments might be due in part to better adherence. Other dietary rules, salt and water restrictions might have been followed more closely by patients with better adherence. They might also have been taking other medications (e.g. antihypertensive and/or antiplatelet drugs) more scrupulously. Hence, selection bias via adherence cannot be ruled out. Furthermore, the group of patients not treated with phosphate binders might have included individuals with low phosphate levels linked to malnutrition. Cinacalcet was markedly taken at a low daily dose, which strongly suggests poor adherence. The EVOLVE trial evidenced a survival benefit from cinacalcet after adjustment for age \[[@pone.0235135.ref021]\]. Data for etelcalcetide are eagerly awaited. Our present results confirmed this advantage, since the cinacalcet was the MBD treatments associated with the greatest observed benefit. This was the only drug with an increasing frequency over the study period among the dialysis patients followed on at least 3 years. Hyperparathyroidism becomes more frequent with longer dialysis vintage. This worsening might be linked at least in part to the observed decreases in the doses of other drugs taken by these patients. Patients should be made more aware of the benefits and risks of MBD treatments.

Our study has the limitation of an observational one and despite its high power could not overcome some bias. The dialysate calcium concentration was treated as a facility-level covariate, whereas the MBD treatment was treated as a patient-level covariate; these two variables did not suffer from the same biases. As mentioned above, the effect of MBD treatments might have been biased by selection of patients with good adherence for those drugs but probably also for other drugs and for dietary measures. The dialysate covariate could not be influenced by a selection or an indication bias because it was built at the facility level. It might have been biased by a center effect, although this is less probable in view of all the combinations of dialysates used. Even those centers using 3 formulas and being highly involved in applying a personalized prescription were not associated with any benefit. The facility-level covariates precluded any estimates of the time of exposure of each patient to the different dialysate calcium concentrations. A further study limitation relates to the lack of laboratory data--especially for calcemia, phosphatemia, and the PTH level and on the ultrafiltration rate. The calcium mass balance from the dialysate could not be evaluated. It remains that calcium mass balance is always higher with higher dialysate calcium. We have no way of checking whether the medical teams were applying the guidelines on adjustments as a function of the laboratory data. The confounding bias induced by the acid type of the dialysate was treated by adjustment. The survivors bias was treated by the time-dependent covariates. The benefit associated with the use of 1.25 mmol/L calcium might have been missed by misclassification and/or by its low rate of use. The combination of the three dialysate calcium concentrations would have been less prone to misclassification because of the stable, frequent levels of use during the study period. Classification of drug use per month was fairly more precise because the data came from a health insurance system that automatically tracks drug purchases for each patient.

In conclusion, our study highlighted the use of various dialysate calcium concentrations across France, and evidenced the centers' widespread use of three dialysate calcium concentrations in line with ERA-EDTA guidelines on personalized prescriptions. The scarce use of the \< 1.5 mmol/L calcium dialysate prevented us from drawing firm conclusion on its relation with survival. Lastly, MBD treatments including an adequate supply of calcium were associated with a significant survival advantage; dialyzed patients should be made aware of this advantage by their physician. Cinacalcet was the MBD treatment associated with the greatest survival advantage.

We thank all REIN registry centers, as listed in the REIN network's annual report (<http://www.agence-biomedecine.fr/Le-programme-REIN>).
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Reviewer \#1: The authors demonstrated no significant difference of different calcium concentration of dialysate on the outcome of patients on hemodialysis using REIN registry.

In the analysis, the authors also showed MBD treatment improved the outcome of these patients.

The findings are not always new, but there are some important implications that clinical practice to control MBD is more important than calcium concentration of dialysate using large French sample.

Reviewer \#2: In this original paper, Lambert and assocoates analyzed the REIN registry data and reported nn significant difference in mortality depending on dialysate calcium concentration.

Stataical analyses were properly performed.

I have only minor comments.

1\. The authors analysed the effects of dialysate calcium concentration mainly, but also analyzed calcium load bythe use of calcium-containing phosphate binders and vitamin D. Thus, the title can be modified to such as \'No effects of calcium load on mortality in French dialysis patients.\'

Answer: we think that the article is not dealing only with calcium but also with the other treatments for mineral bone disease. So the proposed title is too restricted. In addition, the calcium load of this period is probably far less than before. The decrease of the oral calcium was evidenced by the data of the SNDS and probably made possible that the calcium load of the studied period was no more associated with an increased mortality. This is also true for the dialysate calcium concentration as the calcium concentration \> 1.5 decreased over time. It could be: "No effect of reasonable and appropriate calcium load on mortality in the French dialysis patients", but we did not focus only on calcium.

2\. The resukts were not consistent with previous papers. The authors should discuss the reasons more in details, especially in terms of French practice pattern, food and life style etc.

Answer: No recent randomized study has studied the effect of dialysate calcium load on mortality but only observational ones were published. The sole randomized study disclosed more vascular calcifications with dialysate Ca 1.75 versus 1.25 mmol/L but did not compare Ca 1.5 versus 1.75 or 1.25mmol/L. Additionally they evidenced an effect of dialysate Calcium only in patients having an uncontrolled serum phosphate. At last, the results about dialysate calcium 1.25 mmol/L in our study is limited by the low level of use of this formula. This limitation is discussed as followed : \" Our study was unable to evidence any benefit from the use of 1.25 mmol/L formula probably because of its scarce use with a median percentage per unit below 5%.\" and in the limitation paragraph \" The benefit associated with the use of 1.25 mmol/L calcium might have been missed by misclassification and/or by its low rate of use.\"

Reviewer \#3: This is an interesting and well described research from the REIN study group, showing that there is no effect on survival irrespective of dialysate calcium used, this is a little bit in contrast with what is known.

I have some minor comments:

1\. it would be of great clinical importance and interest to know how long patients were dialysed against either a DCa of less than 1.5 or above 1.5 or higher and what than the effect on survival might be?

Answer: the time of exposure should be a covariate of interest. But the dialysate calcium concentration covariates were facility-level covariates and not individual-level ones. So for each patient, we only had a probability of exposure to each calcium concentration. From these data, we cannot calculate a time of exposure for each dialysate calcium concentration. We added this comment into the limitation section as followed:

Text: The facility-level covariates precluded any estimates of the time of exposure of each patient to the different dialysate calcium concentrations.

2\. do the authors have any information on calcifications of vessels with the different DCa concentrations?

Answer: we haven't any data on calcifications in the registry but we discussed this surrogate endpoint in the discussion.

3\. Is calcium load or calcium mass balance known?

Answer: the oral calcium load was estimated from the SNDS data system and was summarized in the treatments tables ( Tables 4 and 5). The calcium load from the dialysate depends on the free calcium concentration of each patient and as discussed into the limitation section, serum calcium is not available in the database of the REIN registry. We added that the calcium mass balance was unknown because of the lack of biology data on serum free calcium in the registry.

Text: A further study limitation relates to the lack of laboratory data -- especially for calcemia, phosphatemia, and the PTH level. The calcium mass balance during dialysis sessions could not be evaluated . It remains that calcium mass balance is always higher with higher dialysate calcium.

4\. The HR in table 5 suggest that calcium might have a worse effect on survival, could the authors eplain this?

Answer: It might be table 7 as there is no HR in table 5. The dialysate calcium covariate wasn\'t significantly associated with survival and oral calcium HRs depended on the calcium dose. A negative effect on survival was only significant for the first tertile of dose and was discussed line 303 to 305 and 324 to 326.

Reviewer \#4: Overall: Lambert and colleagues perform a longitudinal analysis of data from the French REIN registry to evaluate the association of facility level DCa use with MBD medication use at the patient level and all-cause mortality after 3 years. They find that the majority of facilities used a DCa concentration of 1.5mmol/L and over the course of 3 years, the proportion of those using \>1.5mmol/L decreased while those using \<1.5mmol/L increased. The investigators found no effect of higher or lower than DCa 1.5 mmol/L to be associated with mortality and only the MBD therapies were associated with mortality. My comments are below.

Major:

1\. Given that the comparison really is looking at DCa \<1.5 or DCa \>1.5 with the bulk of the population actually using DCa = 1.5, I think the analysis would be better suite being divided into three exposure categories with DCa 1.5 perhaps being the referent group? I worry that any risk of benefit seen the category using DCa \<1.5 may be diluted when combined with those using DCa = 1.5. I understand, that there were only relatively few patients with DCa \<1.5

Answer: In fact, the \< 1.5 and 1.5 mmol/L dialysate calcium concentrations exposures are mixed in the patients' characteristics table (table 3), in the oral treatment description tables (tables 4 and 5) and in the crude events table (table 6) because of its very low level of use. But in the Cox models, the \< 1.5, \> 1.5 were considered separately. We presented the two covariates DCa \< 1.5 and \> 1.5, the third DCa 1.5 being in the reference defined by the absence of use of DCa \< 1.5 or \> 1.5 in table 7. In the DCa \> 1.5 covariate, we compared the centers not using this concentration (reference DCa \> 1.5 equal to zero) with the centers using it at different percentages of use. In the Dca \< 1.5 covariate, we compared the centers not using this concentration (reference DCa \< 1.5 equal to zero) with the centers using it at different percentages of use. Therefore in the Cox model, the DCa \< 1.5 effect was never diluted into the DCa 1.5 but actually compared to centers only using DCa 1.5 and \> 1.5. However we agree that the level of use of DCa \< 1.5 was very low and that\'s why its effect may have been blunted.

2\. Can you please explain why the higher DCa group was also exposed to higher dose of oral calcium (Line 168)

Answer: There is probably a remaining policy in some centers that continue to follow a calcium preferred treatment for hyperparathyroidism and phosphate binding. We found these centers still using calcium as the preferred agent for MBD therapy. But they largely decreased the oral calcium dose and now are more using several formulas instead of Ca \> 1.5 alone.

3\. What is missing from this data is the average volume removal (ultrafiltration) during the dialysis in the various groups. If the reason DCa have an effect of mortality is due to the dose of Ca delivered acutely and chronically, this analysis doesn't account for Ca losses with ultrafiltration which occur depending on the volume removed- as much as 3mEq of Ca removed with 2L UF. Is there a way to adjust for this? Would the analysis not have been more accurate if the MBD treatments also treated as facility level?

Answer: indeed we hadn't any data on ultrafiltration. We add this in the limitation chapter as followed:

Text : A further study limitation relates to the lack of laboratory data -- especially for calcemia, phosphatemia, and the PTH level and on the ultrafiltration rate.

Answer: Patient-level and facility-level covariates are exposed to different bias. We cannot ascertain that a facility level variable would have been more accurate than a patient-level covariate. We agree that they are usually complementary.

4\. Why was this time period chosen? Can you compare data from to 2009 when there may have been a higher prevalence of DCa \>1.5mmol/L?

Answer: the funding was obtained in 2015 and the analyses built on the 4 previous years to obtain the data of the registry. The DCa \> 1.5 mmol/L was still high in France at that period compared to other countries as evidenced in DOPPS and as discussed line 36 (reference 10).

5\. The investigators state that their results are in contrast to existing studies, and I agree. However, no clear explanation is provided as to why theirs are either more reliable or a better analytic approach compared to other studies. This discussion is critical and needs to be flushed out better.

Answer: No randomized study was conducted to evaluate the mortality risk with the different dialysate calcium concentrations (line 280). Only one study having evaluated a surrogate endpoint on vascular calcifications is published (line 281-284, reference 1). All other publications are observational and so exposed to similar bias as our study. Our study is however one of those that benefitted from the more exhaustive information with both dialysate calcium concentrations and oral MBD therapies in a large dataset of patients. Randomized studies remain the gold standard for evidence based medicine but are still very expensive and sometimes inconclusive as discussed for EVOLVE (line 320).

Minor:

1\. Line 89, should be eGFR

Answer: the change was made

2\. The abstract provides no information about the directionality of the association between MBD therapies and mortality

Answer: We mentioned that the association depended on the calcium dose. We added that the improvement on survival was significant for the second and third tertiles of dose as followed:

Text: Depending on the daily dose used, the MBD therapies were associated with survival improvement for calcium, native vitamin D, active vitamin D, sevelamer, lanthanum and cinacalcet in the second and third tertiles of dose.
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